Allarity Therapeutics, Inc. develops personalized cancer treatments as a clinical-stage biopharmaceutical company focused on stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and its DRP® companion diagnostic technology. The company’s updates center on Phase 2 oncology development, advanced ovarian cancer, clinical and scientific data presentations, companion-diagnostic intellectual property, FDA Fast Track status, and potential use of stenoparib in additional tumor settings.
Recurring news also covers operating and financial results, financing activity that supports clinical programs, research collaborations, and governance matters for the Nasdaq-listed company.
Allarity Therapeutics (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, announced that CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 conference in London. The presentation, scheduled for October 1, 2025, will focus on gene expression-based biomarkers for predicting treatment response to stenoparib, the company's dual PARP and WNT pathway inhibitor.
Jensen will also participate in an interview with Oxford Global's editorial team, discussing Allarity's research and DRP® companion diagnostic platform. The interview will be available on Oxford Global's online content portal. One-on-one meetings with the CEO will be available during the conference.
Allarity Therapeutics (NASDAQ: ALLR) has received FDA Fast Track designation for stenoparib, its investigational treatment for advanced ovarian cancer. This designation enables expedited development and review process, including more frequent FDA interactions and potential eligibility for accelerated approval.
The company is currently conducting a Phase 2 clinical trial evaluating stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. The trial, which began enrollment in June 2025, builds on previous Phase 2 data that demonstrated durable clinical benefit, with some patients maintaining treatment for over 22 months.
Allarity Therapeutics (NASDAQ: ALLR) reported significant progress in Q2 2025, highlighted by the initiation of enrollment in their Phase 2 ovarian cancer trial for stenoparib, their dual PARP and WNT pathway inhibitor. The company secured an Australian patent for the Stenoparib DRP® companion diagnostic and established a new service contract with an EU biotech for their medical laboratory.
Financial highlights include a cash position of $17.8 million, implementation of a $2.6 million share repurchase program, and a $2 million reduction in accounts payable. Q2 2025 saw R&D expenses of $2.3 million (up from $1.06M in Q2 2024) and G&A expenses of $1.8 million (down from $2.3M). The company reported a net loss of $2.3 million for Q2 2025.
Notable appointments include Jesper Høiland to the Board of Directors and Jeffrey S. Ervin as CFO, strengthening the company's leadership team.
Allarity Therapeutics (NASDAQ: ALLR) has signed a new commercial agreement with an undisclosed EU-based biotech company for its DRP® platform technology. The agreement includes a non-exclusive global license for selected proprietary Allarity DRP® algorithms in breast cancer and laboratory services from Allarity's Medical Laboratory in Denmark.
The partnership involves advanced transcriptome analysis services to support precision oncology solutions in breast cancer, with committed purchases for laboratory services over the next year. The DRP® platform uses gene expression profiling to predict tumor responses to specific therapies. Allarity currently holds DRPs for over 100 drugs, including both investigational and approved medications.
Allarity Therapeutics (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has appointed Jeff Ervin as its new Chief Financial Officer. Ervin, who brings nearly 20 years of executive leadership experience, succeeds Alexander Epshinsky. He previously served as Co-CFO at NYSE-listed DayDayCook and CEO of NASDAQ-listed IMAC Holdings.
Ervin holds an MBA from Vanderbilt University and will initially join Allarity in a half-time capacity, with potential for full-time employment based on company needs. The company is focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment using its proprietary DRP® patient selection technology.
Allarity Therapeutics (NASDAQ: ALLR) has received a patent acceptance notice from IP Australia for its Stenoparib DRP® companion diagnostic. The acceptance covers 40 claims for the company's proprietary drug-specific Drug Response Predictor (DRP®) technology used in conjunction with stenoparib, their Phase 2 dual PARP and WNT pathway inhibitor for personalized cancer treatment.
The patent will be advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent should be granted within 20 working days. Allarity currently holds 18 granted patents for drug-specific DRPs, including eight in the United States, and has additional Stenoparib DRP® patent applications pending in the U.S., Canada, Japan, China, and India.
Allarity Therapeutics (NASDAQ: ALLR) has announced the dosing of the second patient in its new Phase 2 clinical trial of stenoparib, a dual PARP and WNT pathway inhibitor, for treating advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.
The trial builds upon previous Phase 2 data that showed durable clinical benefit and favorable tolerability with twice-daily dosing. The study aims to evaluate stenoparib as a potential novel, targeted treatment option for patients with limited alternatives. Additionally, the trial will advance Allarity's proprietary Drug Response Predictor (DRP®) companion diagnostic and further study stenoparib's unique WNT-modulating mechanism of action.